AUROBINDO

February 7, 2019

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir,

Sub: Outcome of the Board Meeting held on February 7, 2019.

The Board of Directors of the Company at its meeting held today, February 7, 2019, has inter alia, transacted the following businesses:

1. Approved the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2018 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.
2. We enclose a copy of the Press Release on Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2018.
3. Approved a Second Interim Dividend @125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2018-19. The Company has fixed **February 19, 2019** as the **Record Date** for the purpose of payment of Second Interim Dividend and the same will be paid on or before February 28, 2019.
4. Approved the reappointment of Mr. M.Sitarama Murty (DIN 01694236) as an Independent Director of the Company for the second term subject to the approval of the shareholders. Also approved the Postal Ballot notice for seeking approval of shareholders for re-appointment of Mr. M.Sitarama Murty as an Independent Director of the Company for the second term of two years commencing from April 1, 2019 to March 31, 2021 as well as to continue to hold the position of Non-Executive Independent Director beyond 75 years of age. The Profile of Mr.M.Sitarama Murty is enclosed as **Annexure-I**
5. The Company has entered into a share subscription agreement to invest Rs. 15 crores in Synergy Remedies Private Limited (Synergy), a Tirupathi based pharma company by subscribing to additional equity shares of the said company. After making the said investment, the Company will be holding 19.9% of the share capital of Synergy. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is enclosed as **'Annexure II'.**

The Board meeting commenced at 4.30 p.m and concluded at 7.30 p.m.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. * HYD. *

Enclosures: as above.

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2018

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue from operations**						
	(a) Net sales/ income from operations (refer note 3)	**316,050**	309,038	262,035	**874,250**	774,564	1,004,196
	(b) Other operating income	**8,760**	8,001	6,593	**23,481**	20,279	26,119
	Total revenue from operations	**324,810**	317,039	268,628	**897,731**	794,843	1,030,315
2	**Other Income**						
	(a) Foreign exchange gain (net)	**5,180**	-	2,800	-	5,558	5,853
	(b) Others	**8,507**	418	579	**9,207**	1,871	2,212
	Total other income	**13,687**	418	3,379	**9,207**	7,429	8,065
	Total Income (1+2)	**338,497**	317,457	272,007	**906,938**	802,272	1,038,380
3	**Expenses**						
	(a) Cost of materials consumed	**170,414**	160,899	124,149	**474,710**	370,178	489,327
	(b) Purchases of stock-in-trade	**371**	743	160	**1,367**	330	372
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	**(2,243)**	(1,134)	1,110	**(15,290)**	(24,369)	(33,418)
	(d) Employee benefits expense	**34,986**	33,180	28,318	**100,095**	81,425	113,164
	(e) Finance costs	**4,141**	3,080	1,321	**9,608**	3,548	5,289
	(f) Foreign exchange loss (net) (refer note 7)	-	2,294	-	**2,110**		-
	(g) Depreciation expense	**10,910**	10,094	9,028	**30,370**	26,328	35,483
	(h) Other expenses	**61,450**	60,360	48,461	**169,354**	148,066	193,869
	Total expenses	**280,029**	269,516	212,547	**772,324**	605,506	804,086
4	**Profit before tax (1+2-3)**	**58,468**	47,941	59,460	**134,614**	196,766	234,294
5	Tax expense	**12,117**	9,846	15,028	**27,656**	46,318	53,017
6	**Net profit for the period (4-5)**	**46,351**	38,095	44,432	**106,958**	150,448	181,277
7	Other Comprehensive income - items that will not be reclassified to profit or loss (net of tax)	**(32)**	(1)	(137)	**(96)**	(411)	(218)
8	**Total Comprehensive Income for the period (6+7)**	**46,319**	38,094	44,295	**106,862**	150,037	181,059
9	Paid-up equity share capital (face value Re. 1 per share)	**5,859**	5,859	5,859	**5,859**	5,859	5,859
10	Other equity						992,399
11	Earnings per equity share	**(not annualised)**	(not annualised)	(not annualised)	**(not annualised)**	(not annualised)	(annualised)
	(a) Basic (in Rs.)	**7.91**	6.50	7.58	**18.25**	25.68	30.94
	(b) Diluted (in Rs.)	**7.91**	6.50	7.58	**18.25**	25.68	30.94

NOTES:

1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2 The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 07 February 2019. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2018 and have issued an unmodified opinion.

3 Post implementation of Goods and Services Tax ('GST') with effect from 01 July 2017, revenues from operations is disclosed net of GST. Revenue from operations for the quarter and nine months ended 31 December 2018, quarter ended 30 September 2018 and 31 December 2017 are reported net of GST. The year ended 31 March 2018 and nine months ended 31 December 2017 include excise duty upto 30 June 2017.

4 Effective 01 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Company.

5 The Company operates in only one segment viz., 'Pharmaceutical Products'.

6 Sales of standalone for current quarter include exports of Rs. 263,033 lakhs (31 December 2017: Rs. 223,138 lakhs).

7 Foreign exchange loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.

8 The Board has approved second interim dividend @125% i.e. Re.1.25 (Rupee One and twenty five paise only) per equity share of Re.1 (Rupee One only) for the year 2018-19.

9 Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N. Govindarajan
Managing Director

AUROBINDO PHARMA LTD. HYD.

Place: Hyderabad
Date : 07 February 2019

www.aurobindo.com

B S R & Associates LLP CHARTERED ACCOUNTANTS

FOR IDENTIFICATION PURPOSE ONLY

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone +91 40 7182 2000
Fax +91 40 7182 2399

Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results pursuant to Regulation 33 of the Listing Regulations, 2015

To
Board of Directors of Aurobindo Pharma Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Aurobindo Pharma Limited for the quarter ended 31 December 2018 and the year-to-date results for the period from 01 April 2018 to 31 December 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company in their meeting held on 7 February 2019. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"* specified under Section 143(10) of the Companies Act, 2013 ("the Act"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e., Ind AS prescribed under Section 133 of the Act and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**
Chartered Accountants
ICAI Firm Registration Number: 116231W/ W-100024

Sriram Mahalingam
Partner
Membership No.: 049642

Place: Hyderabad
Date: 7 February 2019

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2018

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue from operations**						
	(a) Net sales/ income from operations (refer note 4)	517,526	466,712	426,899	1,402,394	1,224,424	1,623,287
	(b) Other operating income	9,441	8,428	6,712	24,740	20,651	26,697
	Total revenue from operations	526,967	475,140	433,611	1,427,134	1,245,075	1,649,984
2	**Other Income**						
	(a) Foreign exchange gain (net)	5,045	-	726	-	-	-
	(b) Others	1,340	2,626	2,579	8,339	5,815	10,198
	Total other income	6,385	2,626	3,305	8,339	5,815	10,198
	Total income (1+2)	533,352	477,766	436,916	1,435,473	1,250,890	1,660,182
3	**Expenses**						
	(a) Cost of materials consumed	192,256	187,436	138,371	545,370	420,158	562,937
	(b) Purchases of stock-in-trade	55,184	44,402	44,283	143,099	113,915	160,588
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(8,452)	(27,549)	(904)	(54,467)	(25,746)	(48,251)
	(d) Employee benefits expense	64,980	62,548	54,068	187,141	154,957	213,084
	(e) Finance costs	4,765	3,539	1,886	11,258	5,299	7,771
	(f) Foreign exchange loss (net) (refer note 9)	-	3,973	-	5,744	84	1,676
	(g) Depreciation and amortisation expense	16,312	16,368	13,808	48,133	40,134	55,797
	(h) Other expenses	114,361	105,703	95,235	316,831	283,342	382,774
	Total expenses	439,406	396,420	346,747	1,203,109	992,143	1,336,376
4	**Profit before share of profit of joint ventures, exceptional item and tax (1+2-3)**	93,946	81,346	90,169	232,364	258,747	323,806
5	Share of profit of joint ventures, net of tax	257	24	11	322	258	314
6	**Profit before exceptional item and tax (4+5)**	94,203	81,370	90,180	232,686	259,005	324,120
7	**Exceptional item (refer note 6)**	2,504	2,684	-	5,188	-	-
8	**Profit before tax (6-7)**	91,699	78,686	90,180	227,498	259,005	324,120
9	Tax expense	20,478	17,542	30,694	49,574	69,589	81,828
10	**Net profit for the period (8-9)**	71,221	61,144	59,486	177,924	189,416	242,292
11	Share of profit/(loss) attributable to non-controlling interest	(1)	1	(15)	(7)	(51)	(26)
12	**Net profit after taxes attributable to owners of the Parent Company (10-11)**	71,222	61,143	59,501	177,931	189,467	242,318
13	Other Comprehensive income						
	i) items that will not be reclassified subsequently to profit or loss (net of tax)	(35)	9	(137)	(89)	(433)	(237)
	ii) items that will be reclassified subsequently to profit or loss	(17,309)	19,154	(4,729)	5,371	5,007	15,191
	Total other comprehensive income	(17,344)	19,163	(4,866)	5,282	4,574	14,954
14	**Total Comprehensive income for the period (12+13)**	53,878	80,306	54,635	183,213	194,041	257,272
15	Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859	5,859
16	Other equity						1,162,183
17	Earnings per equity share	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic (in Rs.)	12.15	10.44	10.16	30.37	32.34	41.36
	(b) Diluted (in Rs.)	12.15	10.44	10.16	30.37	32.34	41.36

NOTES:

1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.

3 The above consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 07 February 2019. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2018 and have issued an unmodified opinion.

4 Post implementation of Goods and Services Tax ('GST') with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the quarter and nine months ended 31 December 2018, quarter ended 30 September 2018 and 31 December 2017 are reported net of GST. The year ended 31 March 2018 and nine months ended 31 December 2017 include excise duty upto 30 June 2017.

5 Effective 01 April 2018, the Group has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.

6 Exceptional items for the current period represents acquisition related costs.

7 The Group operates in only one segment viz., 'Pharmaceutical Products'.

8 During the quarter, Aurobindo Pharma USA Inc., USA, has completed the acquisition of a product under development and related assets from ' Advent Pharmaceuiticals Pty Ltd., Australia, through AuroScience Pty Limited, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA.

9 Foreign exchange loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on "Borrowing costs".

10 Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N. Govindarajan
Managing Director

Place: Hyderabad
Date : 07 February 2019

www.aurobindo.com

AUROBINDO PHARMA LTD. HYD.

BSR & Associates LLP CHARTERED ACCOUNTANTS

FOR IDENTIFICATION PURPOSE

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone +91 40 7182 2000
Fax +91 40 7182 2399

Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations

To
The Board of Directors of Aurobindo Pharma Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") of Aurobindo Pharma Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group') and its joint ventures as listed in Annexure I, for the quarter ended 31 December 2018 and year-to-date results for the period from 01 April 2018 to 31 December 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors on 7 February 2019. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'* specified under Section 143(10) of the Companies Act, 2013 ("the Act"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the financial information of 19 subsidiaries included in the Statement, whose unaudited financial information reflect total revenues of Rs. 324,138 lakhs and Rs. 863,195 lakhs for the quarter ended 31 December 2018 and period from 01 April 2018 to 31 December 2018 respectively and total assets of Rs. 934,954 lakhs as at 31 December 2018. This unaudited financial information has been reviewed by other auditors whose reports have been furnished to us, and our conclusion on the Statement, to the extent they have been derived from such unaudited financial information is based solely on the report of such other auditors. Our conclusion is not modified in respect of such matter.

B S R & Associates (a partnership firm with Registration No. BA69226) converted into B S R & Associates LLP (a Limited Liability Partnership with LLP Registration No. AAB-8182) with effect from October 14, 2013

Registered Office:
5th Floor, Lodha Excelus
Apollo Mills Compound
N.M. Joshi Marg, Mahalakshmi
Mumbai - 400 011

Limited Review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations *(continued)*

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's Management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments, if any made by the Company's Management. Our conclusion in so far on the Statement as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the Management of the Company and reviewed by us.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e., Ind AS prescribed under Section 133 of the Act and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**
Chartered Accountants
ICAI Firm Registration Number: 116231W/ W-100024



Sriram Mahalingam
Partner
Membership Number: 049642

Place: Hyderabad
Date: 7 February 2019

Limited Review report *(continued)*

Annexure I

List of subsidiaries and joint ventures

S.No.	Component Name	Country	Relationship
1	APL Research Centre Limited	India	Subsidiary
2	APL Healthcare Limited	India	Subsidiary
3	Auronext Pharma Private Limited	India	Subsidiary
4	Silicon Life Sciences Private Limited	India	Subsidiary
5	Auro Peptides Limited	India	Subsidiary
6	APL Pharma Thai Limited	Thailand	Subsidiary
7	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary
8	Aurobindo Pharma USA Inc.	USA	Subsidiary
9	Natrol LLC	USA	Subsidiary
10	Aurolife Pharma LLC	USA	Subsidiary
11	Auro Health LLC	USA	Subsidiary
12	Auromedics Pharma LLC	USA	Subsidiary
13	Aurobindo Pharma USA LLC (dissolved w.e.f. 31 March 2018, revived w.e.f. 06 June 2018)	USA	Subsidiary
14	Auro AR LLC	USA	Subsidiary
15	Auro Vaccines LLC	USA	Subsidiary
16	Auro Logistics LLC	USA	Subsidiary
17	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
18	Helix Healthcare B.V.	The Netherlands	Subsidiary
19	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
20	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
21	Novagen Pharma (Pty) Limited	South Africa	Joint venture
22	Auro Pharma Inc.	Canada	Subsidiary
23	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
24	Auro Healthcare (Nigeria) Limited	Nigeria	Subsidiary
25	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
26	Aurobindo Pharma Colombia S.A.S	Colombia	Subsidiary
27	Agile Pharma B.V.	The Netherlands	Subsidiary
28	Arrow Generiques SAS	France	Subsidiary
29	1980 Puren Pharma GmbH (formerly Actavis Management GmbH)	Germany	Subsidiary
30	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Subsidiary
31	Aurovitas Spain SA (formerly Actavis Spain S.A)	Spain	Subsidiary
32	Aurobindo Pharma B.V. (formerly Actavis B.V.)	The Netherlands	Subsidiary
33	Aurex B.V. (formerly Pharmacin B.V.)	The Netherlands	Subsidiary
34	Aurobindo Pharma GmbH	Germany	Subsidiary
35	Aurobindo Pharma (Portugal) Unipessoal Limitada (Merged with Generis Farmaceutica S.A w.e.f. 01 April 2018)	Portugal	Subsidiary

Limited Review report *(continued)*

Annexure I ***(continued)***

List of subsidiaries and joint ventures (continued)

S.No.	Component Name	Country	Relationship
36	Laboratorios Aurobindo S.L.	Spain	Subsidiary
37	Aurobindo Pharma (Italia) S.r.l	Italy	Subsidiary
38	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
39	Aurovitas, Unipessoal LDA (Merged with Generis Farmaceutica S.A w.e.f. 01 April 2018)	Portugal	Subsidiary
40	Pharmacin B.V. (formerly Aurex B.V.)	The Netherlands	Subsidiary
41	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary
42	APL Swift Services (Malta) Limited	Malta	Subsidiary
43	Milpharm Limited	United Kingdom	Subsidiary
44	Aurovitas Pharma Polska	Poland	Subsidiary
45	Generis Farmaceutica S.A	Portugal	Subsidiary
46	Mer Medicamentos, Lda. (Merged with Generis Farmaceutica S.A. w.e.f. 01 April 2018)	Portugal	Subsidiary
47	Generis Phar, Unipessoal Lda.	Portugal	Subsidiary
48	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Subsidiary
49	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
50	Hyacinths Pharma Private Limited	India	Subsidiary
51	Raidurgam Developers Limited (formerly Aurobindo Antibiotics Ltd)	India	Joint venture
52	AuroZymes Limited	India	Subsidiary
53	Curepro Parenterals Limited	India	Subsidiary
54	Eugia Pharma Specialities Limited	India	Joint venture
55	Tergene Biotech Private Limited	India	Joint venture
56	Auro Pharma India Private Limited	India	Subsidiary
57	Aurovitas Pharma Ceska republika s.r.o	Czech Republic	Subsidiary
58	Aurovitas Pharma (Taizhou) Ltd	China	Subsidiary
59	Acrotech Biopharma LLC	USA	Subsidiary
60	Purple Bellflower (Pty) Ltd (w.e.f. 23 August 2018)	South Africa	Joint venture
61	Auroscience Pty Ltd (w.e.f. 25 September 2018)	Australia	Subsidiary

NEWS RELEASE

7th February 2019, Hyderabad, India

Aurobindo Pharma Ltd Q3 FY18-19 Financial Results

Consolidated financial results – Q3FY18-19

Amount in INR Cr	Q3 FY18-19	Q3 FY17-18	% Chg	Q2 FY18-19	% Chg
Revenue from Operations	5,269.7	4,336.1	21.5	4,751.4	10.9
EBITDA before Forex and Other income	1,086.4	1,025.6	5.9	1,026.0	5.9
EBITDA %	20.6%	23.7%		21.6%	
PBT before Forex and Exceptional Items	889.0	894.4	-0.6	853.2	4.2
Net Profit after JV share, minority interest	712.2	595.0	19.7	611.4	16.5

Key Highlights of Q3FY19 consolidated financials


- Revenue from Operations at INR 5,269.7 Cr, witnessed a strong growth of 21.5% over corresponding previous period
  - US formulation sales of INR 2,433.2 Cr vs INR 1,909.6 Cr in Q3FY18, registering a robust growth of 27.4% YoY
  - Europe formulation sales at INR 1,292.8 Cr, an increase of 10.3% against Q3 last year
  - Growth Markets posted a strong growth of 36.1% YoY to INR 340.5 Cr
  - ARV sales at INR 281.3 Cr vs. INR 238.9 Cr, an increase of 17.8% over corresponding previous period
  - API sales witnessed a healthy growth of 20.4% YoY to INR 921.7 Cr
- EBIDTA before Forex and Other income at INR 1,086.4 Cr vs INR 1,025.6 Cr in Q3 last year, grew by 5.9% ; EBITDA margin for the quarter was at 20.6%
- Net Profit after JV share, minority interest at INR 712.2 Cr as against INR 595.0 Cr in the corresponding previous period, witnessing a growth of 19.7% YoY.
- Basic & Diluted EPS is INR 12.15 per share.
- Board has approved second interim dividend @ 125% i.e., INR 1.25 per equity share of INR 1/- for the year FY18-19
- Research & Development (R&D) spend at INR 254.6 Cr, 4.8% of revenues
- Received final approval for 14 ANDAs and tentative approval for 1 ANDA from USFDA


Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said: *"We have delivered a robust revenue growth of 22%, driven by strong growth across all business segments and markets. Gross profit could have been better, but for certain one-time expenses. Our execution strength, pipeline evolution and recent acquisitions will drive the future growth."*

Operational Performance (Consolidated):

Amount in INR Cr	Q3 FY18-19	Q3 FY17-18	% Chg	Q2 FY18-19	% Chg
Formulations					
USA	2,433.2	1,909.6	27.4	2,226.8	9.3
Europe	1,292.8	1,171.6	10.3	1,156.5	11.8
Growth Markets	340.5	250.2	36.1	307.5	10.8
ARV	281.3	238.9	17.8	244.0	15.3
Total Formulations	**4,347.8**	**3,570.2**	**21.8**	**3,934.8**	**10.5**
Active Pharmaceuticals Ingredients (API)					
Betalactum	557.7	536.6	3.9	513.4	8.6
Non Betalactum	364.1	229.2	58.9	303.2	20.1
Total API	**921.7**	**765.7**	**20.4**	**816.6**	**12.9**
Consolidated Sales	**5,269.6**	**4,336.0**	**21.5**	**4,751.4**	**10.9**
Dossier Income	0.1	0.1		0.0	
Revenue from Operations	**5,269.7**	**4,336.1**	**21.5**	**4,751.4**	**10.9**

Consolidated Revenue breakup - Geography & segment wise





Formulations

Formulation sales for the quarter increased by 21.8% YoY to INR 4,347.8 Cr and accounted for 82.5% of total revenues

US Formulations

- US sales of INR 2,433.2 Cr compared to INR 1,909.6 Cr in Q3FY18, witnessing a strong growth of 27.4% YoY. On a constant currency basis, sales increased by 14.7% YoY. US accounted for 46.2% of total revenues.
- The company filed 10 ANDAs with USFDA including 4 ANDAs for injectable products
- Received final approval for 14 ANDAs and tentative approval for 1 ANDA

- As on 31st Dec 2018, on a cumulative basis, the company filed 519 ANDAs with USFDA and received approval for 397 ANDAs including 28 tentative* approvals
- The company has launched 7 products including 2 injectables during the quarter

**Tentative approvals include 9 ANDAs approved under PEPFAR.*

EU Formulations

Sales from EU formulations in Q3FY18-19 increased by 10.3% YoY to INR 1,292.8 Cr. The business accounted for 24.5% of revenues. In Euro terms, sales increased by 2.5% YoY.

ARV Formulations

ARV business sales increased by 17.8% YoY to INR 281.3 Cr compared to INR 238.9 Cr in Q3FY18 and accounted for 5.3% of revenues.

Growth Markets Formulations

Sales from Growth Markets formulations posted a strong growth of 36.1% YoY to INR 340.5 Cr in Q3FY18-19 and accounted for 6.5% of revenues.

API business

API business posted a growth of 20.4% to INR 921.7 Cr and contributed 17.5% of the total revenue during the quarter. The growth was on the back of increase in Non-Betalactum segment. The company filed 1 DMFs with USFDA during the quarter taking total DMFs filing to 236 as on 31st Dec 2018.

Global Regulatory Filings:

Filings	Q3 FY18-19	Cumulative Filings as on 31st Dec 2018
ANDAs (including filings made from Aurobindo USA)	10	519
DMFs (including filings made from AuroNext and AuroPeptide)	1	236
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe. South Africa and Canada)	43	3,553
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	46	2,880

USFDA approvals received in Q3 FY18-19:

Final Approvals

1	Abacavir Sulfate / Lamivudine (gEpzicom) Tab 600 mg / 300 mg Tab	Anti-Retrovirals
2	Palonosetron Hydrochloride (gAloxi) Inj 0.25 mg/5 mL	Gastrointestinal
3	Ketorolac Tromethamine (gAcular LS) Sol 0.4% w/v	Ophthalmic
4	Paricalcitol (gZemplar) Inj 2 mcg/mL and 5 mcg/mL	Calcium Regulator
5	Vecuronium Bromide Inj 10 mg/vial and 20 mg/vial	CNS
6	Azithromycin (gZithromax) Oral Susp 100 mg per 5 mL and 200 mg per 5 mL	Antibiotic
7	Argatroban Inj in 0.9% Sodium Chloride 50 mg/50 mL	Anti-Thrombotic
8	Teriflunomide (gAubagio) Tab 7 mg and 14 mg	CNS
9	Glycopyrrolate(gRobinul) Inj 0.2 mg/mL	Anti-Cholinergic
10	Silodosin (gRapaflo) Cap 4 mg and 8 mg	Genitourinary
11	Potassium Chloride (gKlor-Con) ER Tab 8 mEq and 10 mEq	Electrolyte Replacement
12	Progesterone Injection 500 mg/10 mL	Steroid Hormone
13	Methylphenidate HCl (gRitalin) Tab 5 mg, 10 mg and 20 mg	CNS
14	Progesterone (gPrometrium) Cap 100 mg and 200 mg	Harmonal Drug

Tentative approvals

1	Mirabegron (gMyrbetriq) ER Tab 50 mg	Genitourinary

Earnings call details

The company will host an earnings call at 8.30 AM IST on February 8th 2019, to discuss the performance and answer any questions from participants.

Participants can dial-in on the numbers below
Primary Number: +91 22 6280 1437 / +91 22 7115 8825
Local Access Number: +91 70456 71221 (Available all over India)

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

For further information, please contact:

Krishna Kiran
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com (Rs. In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2018

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	**31.12.2018**	31.12.2017	**31.03.2018**
		Unaudited	Unaudited	Unaudited	**Unaudited**	Unaudited	**Audited**
1	**Revenue from operations**						
	(a) Net sales/ income from operations (refer note 4)	**517,526**	466,712	426,899	**1,402,394**	1,224,424	1,623,287
	(b) Other operating income	**9,441**	8,428	6,712	**24,740**	20,651	26,697
	Total revenue from operations	**526,967**	475,140	433,611	**1,427,134**	1,245,075	1,649,984
2	**Other income**						
	(a) Foreign exchange gain (net)	**5,045**	-	726	**-**	-	-
	(b) Others	**1,340**	2,626	2,579	**8,339**	5,815	10,198
	Total other income	**6,385**	2,626	3,305	**8,339**	5,815	10,198
	Total income (1+2)	**533,352**	477,766	436,916	**1,435,473**	1,250,890	1,660,182
3	**Expenses**						
	(a) Cost of materials consumed	**192,256**	187,436	138,371	**545,370**	420,158	562,937
	(b) Purchases of stock-in-trade	**55,184**	44,402	44,283	**143,099**	113,915	160,588
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	**(8,452)**	(27,549)	(904)	**(54,467)**	(25,746)	(48,251)
	(d) Employee benefits expense	**64,980**	62,548	54,068	**187,141**	154,957	213,084
	(e) Finance costs	**4,765**	3,539	1,886	**11,258**	5,299	7,771
	(f) Foreign exchange loss (net) (refer note 9)	**-**	3,973	-	**5,744**	84	1,676
	(g) Depreciation and amortisation expense	**16,312**	16,368	13,808	**48,133**	40,134	55,797
	(h) Other expenses	**114,361**	105,703	95,235	**316,831**	283,342	382,774
	Total expenses	**439,406**	396,420	346,747	**1,203,109**	992,143	1,336,376
4	**Profit before share of profit of joint ventures, exceptional item and tax (1+2-3)**	**93,946**	81,346	90,169	**232,364**	258,747	323,806
5	Share of profit of joint ventures, net of tax	**257**	24	11	**322**	258	314
6	**Profit before exceptional item and tax (4+5)**	**94,203**	81,370	90,180	**232,686**	259,005	324,120
7	**Exceptional item (refer note 6)**	**2,504**	2,684	-	**5,188**	-	-
8	**Profit before tax (6-7)**	**91,699**	78,686	90,180	**227,498**	259,005	324,120
9	Tax expense	**20,478**	17,542	30,694	**49,574**	69,589	81,828
10	**Net profit for the period (8-9)**	**71,221**	61,144	59,486	**177,924**	189,416	242,292
11	Share of profit/(loss) attributable to non-controlling interest	**(1)**	1	(15)	**(7)**	(51)	(26)
12	**Net profit after taxes attributable to owners of the Parent Company (10-11)**	**71,222**	61,143	59,501	**177,931**	189,467	242,318
13	Other Comprehensive income						
	i) items that will not be reclassified subsequently to profit or loss (net of tax)	**(35)**	9	(137)	**(89)**	(433)	(237)
	ii) items that will be reclassified subsequently to profit or loss	**(17,309)**	19,154	(4,729)	**5,371**	5,007	15,191
	Total other comprehensive income	**(17,344)**	19,163	(4,866)	**5,282**	4,574	14,954
14	**Total Comprehensive income for the period (12+13)**	**53,878**	80,306	54,635	**183,213**	194,041	257,272
15	Paid-up equity share capital (face value Re. 1 per share)	**5,859**	5,859	5,859	**5,859**	5,859	5,859
16	Other equity						1,162,183
17	Earnings per equity share	**(not annualised)**	(not annualised)	(not annualised)	**(not annualised)**	(not annualised)	(annualised)
	(a) Basic (in Rs.)	**12.15**	10.44	10.16	**30.37**	32.34	41.36
	(b) Diluted (in Rs.)	**12.15**	10.44	10.16	**30.37**	32.34	41.36

NOTES:

1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.

2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.

3 The above consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 07 February 2019. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2018 and have issued an unmodified opinion.

4 Post implementation of Goods and Services Tax ('GST') with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the quarter and nine months ended 31 December 2018, quarter ended 30 September 2018 and 31 December 2017 are reported net of GST. The year ended 31 March 2018 and nine months ended 31 December 2017 include excise duty upto 30 June 2017.

5 Effective 01 April 2018, the Group has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.

6 Exceptional items for the current period represents acquisition related costs.

7 The Group operates in only one segment viz., 'Pharmaceutical Products'.

8 During the quarter, Aurobindo Pharma USA Inc., USA, has completed the acquisition of a product under development and related assets from ' Advent Pharmaceuiticals Pty Ltd., Australia, through AuroScience Pty Limited, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA.

9 Foreign exchange loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on "Borrowing costs".

10 Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

Place: Hyderabad
Date : 07 February 2019

www.aurobindo.com

N. Govindarajan
Managing Director

AUROBINDO

Annexure -I

Profile of Mr.M.Sitarama Murty

Mr. M.Sitarama Murty (DIN 01694236), aged 75 years is a B.Sc., (Hons.) graduate and a M.Sc., (Electronics) postgraduate. He is professionally qualified as CAIIB, with all India 1st Rank in Part-II. Mr. Murthy has over three decades of experience as a banker and has held various positions within SBI and its Associates. He retired as Managing Director & CEO of State Bank of Mysore, Bangalore, in the year 2003. His specialized areas of interest are International Banking, Foreign Exchange, Money Markets, Funds Management, Credit Management, Rural Development, Computerization, Commercial Law and Systems and Procedures. He has authored several books on banking systems and contributes regular articles to financial magazines / newspapers. Given his background, experience and contribution made by him during his tenure with the Company, the continued association of Mr. M.Sitarama Murty would be beneficial to the Company.

He is not related to any promoter, Director / Key Managerial Personnel of the Company. Further, the Company specifically affirms that Mr. M.Sitarama Murty is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Annexure -II

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	**i) Name of the Target :** Synergy Remedies Private Limited (Synergy) Registered Office: D.No.7-1-397/13, Near Community Hall, Sanjeev Reddy Nagar, Hyderabad 500038 **ii) Details of the Target:** Synergy was incorporated in the year 2011 and started commercial production in the financial year 2016-17. Turnover for the financial year 2017-18 was Rs.15.5 crores and for the financial year 2016-17 was Rs.66.35 lakhs
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	Acquisition will not fall within the related party transaction.
c) Industry to which the entity being acquired belongs;	Pharmaceutical industry.

d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To ensure assured supplies of some of the APIs and intermediates.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	No approval is required.
f) Indicative time period for completion of the acquisition;	By end of February 2019.
g) Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
h) Cost of acquisition or the price at which the shares are acquired;	Rs.15 crores (subscription of equity shares of Rs.10/- each at a premium of Rs.4.30 per equity share)
i) Percentage of shareholding / control acquired and / or number of shares acquired;	After subscription, the Company will be holding 19.9% of the equity share capital Synergy.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Synergy is a pharmaceutical company manufacturing API & Intermediates. Synergy has a factory at Plot No.74 A & Plot No.77 A, Gajulamandyam, APIIC Industrial Estate, Tirupathi, Andhra Pradesh and has 10 licensed API products. Synergy was incorporated in the year 2011 and started commercial production in the financial year 2016-17. Turnover for the financial year 2017-18 was Rs.15.5 crores and the turnover for the financial year 2016-17 was Rs.66.35 lakhs.

AUROBINDO PHARMA LTD. HYD.